Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From Jun 2019 to Jun 2024
Hana Biosciences (AMEX: HBX), a South San
Francisco-based biopharmaceutical company focused on advancing cancer
care, will present at the 3rd Annual PIPES Conference, on Thursday,
Oct. 27, 2005, at 9 a.m., 9:30 a.m. and 10 a.m. The presentation will
take place in the Morgan Room at The Waldorf Astoria on 301 Park
Avenue, New York, New York.
Fred Vitale, vice president of business development for Hana
Biosciences, will provide an overview of the market potential of the
company's well-rounded oncology pipeline to an estimated audience of
1,000 investment professionals focused primarily on small
capitalization companies.
About Hana Biosciences
Hana Biosciences Inc. is a South San Francisco, Calif.-based
biopharmaceutical company that acquires, develops, and commercializes
innovative products to advance cancer care. The company is committed
to creating value by building a world-class team, accelerating the
development of lead product candidates, expanding its pipeline by
being the alliance partner of choice, and nurturing a unique company
culture. Additional information on Hana Biosciences can be found at
www.hanabiosciences.com.
This press release contains forward-looking statements that
involve risks and uncertainties that could cause Hana's actual results
to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual outcomes
and results to differ materially from these statements. Among other
things, there can be no assurances that any of Hana's development
efforts relating to its product candidates will be successful. Other
risks that may affect forward-looking information contained in this
press release include the possibility of being unable to obtain
regulatory approval of Hana's product candidates, the risk that the
results of clinical trials may not support Hana's claims, Hana's
reliance on third-party researchers to develop its product candidates
and its lack of experience in developing pharmaceutical products.
Additional risks are described in the company's Annual Report on Form
10-KSB for the year ended Dec. 31, 2004. Hana assumes no obligation to
update these forward-looking statements, except as required by law.